Vor Biopharma Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VOR research report →
Companywww.vorbio.com
Vor Biopharma, Inc. , a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies.
- CEO
- Jean-Paul Kress
- IPO
- 2021
- Employees
- 159
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $106.58M
- P/E
- -0.01
- P/S
- 0.00
- P/B
- -0.04
- EV/EBITDA
- 0.05
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 87.31%
- ROIC
- -76.08%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-695,981,000 · -495.29%
- EPS
- $-70.50 · -107.35%
- Op Income
- $-371,642,000
- FCF YoY
- -43.81%
Performance & Tape
- 52W High
- $65.80
- 52W Low
- $3.30
- 50D MA
- $14.98
- 200D MA
- $20.73
- Beta
- 1.75
- Avg Volume
- 1.03M
Get TickerSpark's AI analysis on VOR
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 22, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 165,150 |
| Apr 17, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 458,411 |
| Apr 20, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 171,963 |
| Apr 13, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 530,610 |
| Apr 14, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 153,735 |
| Apr 15, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 53,644 |
| Apr 8, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 353,242 |
| Apr 8, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 130,862 |
| Apr 9, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 135,201 |
| Apr 10, 26 | RA CAPITAL MANAGEMENT, L.P. | sell | 828 |
Our VOR Coverage
We haven't published any research on VOR yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VOR Report →